Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-294.1M
Cash
562.4M
Avg Qtr Burn
-63.99M
Short % of Float
8.13%
Insider Ownership
8.82%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Izokibep Details Hidradenitis suppurativa | Phase 3 Update | |
Lonigutamab Details Thyroid Eye Disease , Eye disease | Phase 3 Initiation | |
Izokibep Details Axial spondyloarthritis | Phase 3 Initiation | |
Izokibep Details Psoriatic arthritis | Phase 2/3 Data readout | |
SLRN-517 Details Allergy, Inflammatory disease, KIT/Mast cell diseases | Phase 1/2 Data readout | |
Izokibep Details Uveitis , Eye disease | Failed Discontinued |